Signaling Pathways
Signaling Pathways(信号通路)
- Proteases(63)
- Apoptosis(1190)
- Chromatin/Epigenetics(17)
- Metabolism(420)
- MAPK Signaling(32)
- Tyrosine Kinase(97)
- DNA Damage/DNA Repair(62)
- PI3K/Akt/mTOR Signaling(56)
- Microbiology & Virology(68)
- Cell Cycle/Checkpoint(205)
- Ubiquitination/ Proteasome(43)
- JAK/STAT Signaling(13)
- TGF-β / Smad Signaling(30)
- Angiogenesis(85)
- GPCR/G protein(3)
- Stem Cell(27)
- Membrane Transporter/Ion Channel(273)
- Cancer Biology(514)
- Endocrinology and Hormones(168)
- Neuroscience(462)
- Obesity, Appetite Control & Diabetes(9)
- Peptide Inhibitors and Substrate(1)
- Other Signal Transduction(141)
- Immunology/Inflammation(1111)
- Cardiovascular(63)
- Vitamin D Related
- Antibody-drug Conjugate/ADC Related
- PROTAC(254)
- Ox Stress Reagents(25)
- Others(1718)
- Antiparasitics(21)
- Toxins(90)
Signaling Pathways 相关产品(35130)
- GC10416MethimazoleCAS: 60-56-0纯度: >98.00% / >99.50%
Methimazole是一种抗甲状腺药物，具有抗炎活性，抑制prostaglandin H synthase的IC 50 值为10μM。
- GC10466EMD-1214063CAS: 1100598-32-0纯度: >98.00%
EMD-1214063（Tepotinib，MSC2156119J）是一种新型强效、高选择性、可逆、ATP 竞争性小分子 c-Met 抑制剂。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10415 | Tezampanel | 154652-83-2 | - | |
AMPA receptor antagonist | ||||
| GC10416 | Methimazole | 60-56-0 | >98.00% / >99.50% | |
Methimazole是一种抗甲状腺药物，具有抗炎活性，抑制prostaglandin H synthase的IC 50 值为10μM。 | ||||
| GC10420 | Apremilast (CC-10004) | 608141-41-9 | >99.50% | |
An orally available PDE4 inhibitor | ||||
| GC10423 | RG2833 | 1215493-56-3 | >98.00% | |
An HDAC inhibitor | ||||
| GC10424 | Tolbutamide | 64-77-7 | >99.50% | |
A SUR1/K ir 6.2 channel inhibitor | ||||
| GC10440 | TCS 183 | - | - | |
competitive inhibitor of GSK-3β (Ser9) phosphorylation | ||||
| GC10442 | MK-8745 | 885325-71-3 | >99.00% | |
An Aurora A kinase inhibitor | ||||
| GC10443 | Meclofenoxate hydrochloride | 3685-84-5 | >98.00% | |
A nootropic agent | ||||
| GC10446 | CC-930 | 899805-25-5 | >99.50% | |
A potent JNK inhibitor | ||||
| GC10447 | Isradipine (Dynacirc) | 75695-93-1 | >99.00% | |
An L-type calcium channel blocker | ||||
| GC10448 | Bivalirudin Trifluoroacetate | 128270-60-0 | - | |
A thrombin inhibitor | ||||
| GC10450 | PRX-08066 | 866206-54-4 | - | |
A 5-HT 2B receptor antagonist | ||||
| GC10451 | U-73122 | 112648-68-7 | >98.00% | |
U-73122是有效的、选择性的磷脂酶C（PLC）抑制剂，IC 50 值约为1-2.1μM，也可抑制5-脂氧合酶（5-LO）。 | ||||
| GC10454 | Acemetacin | 53164-05-9 | >99.50% | |
An NSAID | ||||
| GC10455 | BMS-509744 | 439575-02-7 | - | |
BMS-509744 是一种有效的、选择性的和 ATP 竞争性的 Itk 抑制剂，IC50 为 19 nM。 | ||||
| GC10460 | Rizatriptan Benzoate | 145202-66-0 | >99.50% | |
A 5-HT 1B and 5-HT 1D receptor agonist | ||||
| GC10461 | Phenformin HCl | 834-28-6 | >98.00% | |
An antihyperglycemic biguanide | ||||
| GC10463 | SB 216763 | 280744-09-4 | >99.00% | |
SB 216763是一种强效、选择性且ATP竞争性的GSK-3抑制剂，显著作用于GSK-3α和GSK-3β，其IC50仅为34.3 nM。 | ||||
| GC10466 | EMD-1214063 | 1100598-32-0 | >98.00% | |
EMD-1214063（Tepotinib，MSC2156119J）是一种新型强效、高选择性、可逆、ATP 竞争性小分子 c-Met 抑制剂。 | ||||
| GC10467 | Irbesartan | 138402-11-6 | >98.50% | |
Irbesartan是一种血管紧张素II受体（AT1）拮抗剂。 | ||||
| GC10468 | 4EGI-1 | 315706-13-9 | >98.50% | |
An inhibitor of mRNA translation | ||||
| GC10473 | AMD 3465 | 185991-24-6 | - | |
A CXCR4 receptor antagonist | ||||
| GC10474 | Laquinimod (ABR-215062) | 248281-84-7 | >98.00% | |
An immunomodulator | ||||
| GC10478 | Mizolastine dihydrochloride | 1056596-82-7 | - | |
A histamine H 1 receptor antagonist | ||||